Skip to main content

Session 1: Current efficacy trial design approaches – challenges and lessons learned

Virtual workshop series

October 2020 to May 2021

Workshop home Session 2 Session 3

The first session of the virtual workshop aims to reflect on current trial designs and lessons learnt (introductory talks). This session is supported by six bite-size presentations and a panel discussion of the current scientific approaches for establishing efficacy of vaccines in the broader context of PrEP.

Help us frame the live conversation on 27 October 2020 by watching these bite-size talks and submitting your questions and comments ahead of time using the link under each presentation. You can also email us at and, of course, get in touch if you need help navigating the event.

Prep considerations for the MOSAICO trial (S1-03), Susan Buchbinder, MD, University of California San Francisco, USA
Community-informed efforts towards the MOSAICO study (S1-04), Stephaun Wallace, PhD, MS, Fred Hutchinson Cancer Research Center – University of Washington – Seattle, USA
HPTN 083: Where did we go right? (S1-05), Raphael Landovitz, MD, University of California, USA
Contingency plans: modelling effectiveness using counterfactuals (S1-06), Deborah Donnell, PhD, Fred Hutchinson Cancer Research Center – University of Washington – Seattle, USA
PrEPVacc concepts – registrational cohort and prequalification period (S1-07), Eugene Ruzagira, MBChB, MPH, PhD, MRC/UVRI Uganda Research Unit, Entebbe, Uganda
Pre-randomization incidence can approximate a control group, David Glidden, PhD, University of California San Francisco, San Francisco, USA

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.